Epidemiology of Chronic Kidney Disease in Heart Failure

Heart Failure Clinics

Volumn 4, Issue 4, 2008, Pages 387-399

  Ahmed, Ali ^a,b   Campbell, Ruth C ^a,b  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b BIRMINGHAM VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; POTASSIUM;

AGE; BODY MASS; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; COMORBIDITY; CORONARY STENT; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DYSPNEA; ECHOCARDIOGRAPHY; EDUCATIONAL STATUS; ETHNICITY; GERIATRIC DISORDER; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HOSPITALIZATION; HUMAN; INCIDENCE; MICROALBUMINURIA; MORTALITY; PATHOPHYSIOLOGY; PATIENT CARE; POTASSIUM BLOOD LEVEL; PROGNOSIS; PULMONARY HYPERTENSION; REVIEW; RISK FACTOR;

AGED, 80 AND OVER; FEMALE; GLOMERULAR FILTRATION RATE; HEART FAILURE; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PROGNOSIS; RISK FACTORS; UNITED STATES;

EID: 50149096905     PISSN: 15517136     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hfc.2008.03.008     Document Type: Review

References (85)

1. Rosamond W., Flegal K., Friday G., et al. Heart disease and stroke statistics-2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 115 (2007) e69-e171
2. National Heart, Lung and Blood Institute, National Institutes of Health. Congestive heart failure in the United States: a new epidemic 1996.
3. Ahmed A. DEFEAT heart failure: clinical manifestations, diagnostic assessment, and etiology of geriatric heart failure. Heart Fail Clin 3 (2007) 389-402
4. Redfield M.M. Heart failure-an epidemic of uncertain proportions. N Engl J Med 347 (2002) 1442-1444
5. Adams Jr. K.F., Fonarow G.C., Emerman C.L., et al. Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). Am Heart J 149 (2005) 209-216
6. Heywood J.T., Fonarow G.C., Costanzo M.R., et al. High prevalence of renal dysfunction and its impact on outcome in 118,465 patients hospitalized with acute decompensated heart failure: a report from the ADHERE database. J Card Fail 13 (2007) 422-430
7. Gottdiener J.S., Arnold A.M., Aurigemma G.P., et al. Predictors of congestive heart failure in the elderly: the Cardiovascular Health Study. J Am Coll Cardiol 35 (2000) 1628-1637
8. Yamagata K., Ishida K., Sairenchi T., et al. Risk factors for chronic kidney disease in a community-based population: a 10-year follow-up study. Kidney Int 71 (2007) 159-166
9. Stevens L.A., Coresh J., Greene T., et al. Assessing kidney function: measured and estimated glomerular filtration rate. N Engl J Med 354 (2006) 2473-2483
10. The National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 39 (2002) S1-S266
11. Stevens L.A., Coresh J., Feldman H.I., et al. Evaluation of the modification of diet in renal disease study equation in a large diverse population. J Am Soc Nephrol 18 (2007) 2749-2757
12. Shlipak M.G., Katz R., Sarnak M.J., et al. Cystatin C and prognosis for cardiovascular and kidney outcomes in elderly persons without chronic kidney disease. Ann Intern Med 145 (2006) 237-246
13. Randers E., Erlandsen E.J., Pedersen O.L., et al. Serum cystatin C as an endogenous parameter of the renal function in patients with normal to moderately impaired kidney function. Clin Nephrol 54 (2000) 203-209
14. Hojs R., Bevc S., Ekart R., et al. Serum cystatin C as an endogenous marker of renal function in patients with mild to moderate impairment of kidney function. Nephrol Dial Transplant 21 (2006) 1855-1862
15. Knight E.L., Verhave J.C., Spiegelman D., et al. Factors influencing serum cystatin C levels other than renal function and the impact on renal function measurement. Kidney Int 65 (2004) 1416-1421
16. Herget-Rosenthal S., Bokenkamp A., and Hofmann W. How to estimate GFR-serum creatinine, serum cystatin C or equations?. Clin Biochem 40 (2007) 153-161
17. Justesen T.I., Petersen J.L., Ekbom P., et al. Albumin-to-creatinine ratio in random urine samples might replace 24-h urine collections in screening for micro- and macroalbuminuria in pregnant woman with type 1 diabetes. Diabetes Care 29 (2006) 924-925
18. Ahmed A., Rich M.W., Sanders P.W., et al. Chronic kidney disease associated mortality in diastolic versus systolic heart failure: a propensity matched study. Am J Cardiol 99 (2007) 393-398
19. Cowie M.R., Komajda M., Murray-Thomas T., et al. Prevalence and impact of worsening renal function in patients hospitalized with decompensated heart failure: results of the prospective outcomes study in heart failure (POSH). Eur Heart J 27 (2006) 1216-1222
20. Damman K., Navis G., Voors A.A., et al. Worsening renal function and prognosis in heart failure: systematic review and meta-analysis. J Card Fail 13 (2007) 599-608
21. Ezekowitz J., McAlister F.A., Humphries K.H., et al. The association among renal insufficiency, pharmacotherapy, and outcomes in 6427 patients with heart failure and coronary artery disease. J Am Coll Cardiol 44 (2004) 1587-1592
22. Hillege H.L., Girbes A.R., de Kam P.J., et al. Renal function, neurohormonal activation, and survival in patients with chronic heart failure. Circulation 102 (2000) 203-210
23. Hillege H.L., Nitsch D., Pfeffer M.A., et al. Renal function as a predictor of outcome in a broad spectrum of patients with heart failure. Circulation 113 (2006) 671-678
24. Go A.S., Yang J., Ackerson L.M., et al. Hemoglobin level, chronic kidney disease, and the risks of death and hospitalization in adults with chronic heart failure: the Anemia in Chronic Heart Failure Outcomes and Resource Utilization (ANCHOR) Study. Circulation 113 (2006) 2713-2723
25. Campbell RC, Sui X, Filippatos G, et al. Association of chronic kidney disease and outcomes in chronic heart failure: a propensity-matched study. Submitted for publication.
26. Levin A., Thompson C.R., Ethier J., et al. Left ventricular mass index increase in early renal disease: impact of decline in hemoglobin. Am J Kidney Dis 34 (1999) 125-134
27. Al-Ahmad A., Rand W.M., Manjunath G., et al. Reduced kidney function and anemia as risk factors for mortality in patients with left ventricular dysfunction. J Am Coll Cardiol 38 (2001) 955-962
28. McClellan W.M., Flanders W.D., Langston R.D., et al. Anemia and renal insufficiency are independent risk factors for death among patients with congestive heart failure admitted to community hospitals: a population-based study. J Am Soc Nephrol 13 (2002) 1928-1936
29. Silverberg D.S., Wexler D., Blum M., et al. The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe, resistant congestive heart failure improves cardiac and renal function and functional cardiac class, and markedly reduces hospitalizations. J Am Coll Cardiol 35 (2000) 1737-1744
30. Levin A., Djurdjev O., Thompson C., et al. Canadian randomized trial of hemoglobin maintenance to prevent or delay left ventricular mass growth in patients with CKD. Am J Kidney Dis 46 (2005) 799-811
31. Singh A.K., Szczech L., Tang K.L., et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 355 (2006) 2085-2098
32. Drueke T.B., Locatelli F., Clyne N., et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 355 (2006) 2071-2084
33. Levin A., Bakris G.L., Molitch M., et al. Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. Kidney Int 71 (2007) 31-38
34. Russo D., Palmiero G., De Blasio A.P., et al. Coronary artery calcification in patients with CRF not undergoing dialysis. Am J Kidney Dis 44 (2004) 1024-1030
35. Ketteler M., Schlieper G., and Floege J. Calcification and cardiovascular health: new insights into an old phenomenon. Hypertension 47 (2006) 1027-1034
36. Schiffrin E.L., Lipman M.L., and Mann J.F. Chronic kidney disease: effects on the cardiovascular system. Circulation 116 (2007) 85-97
37. Hunt S.A., Abraham W.T., Chin M.H., et al. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). Developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation. Endorsed by the Heart Rhythm Society. Circulation 112 (2005) e154-e235
38. Masoudi F.A., Rathore S.S., Wang Y., et al. National patterns of use and effectiveness of angiotensin-converting enzyme inhibitors in older patients with heart failure and left ventricular systolic dysfunction. Circulation 110 (2004) 724-731
39. Ahmed A., Allman R.M., DeLong J.F., et al. Age-related underutilization of angiotensin-converting enzyme inhibitors in older hospitalized heart failure patients. South Med J 95 (2002) 703-710
40. Bakris G.L., and Weir M.R. Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: is this a cause for concern?. Arch Intern Med 160 (2000) 685-693
41. Maschio G., Alberti D., Janin G., et al. Effect of the angiotensin-converting enzyme inhibitor benazepril on the progression of chronic renal insufficiency: the Angiotensin-Converting Enzyme Inhibition in Progressive Renal Insufficiency Study Group. N Engl J Med 334 (1996) 939-945
42. Rothwell P.M. Treating individuals 2. Subgroup analysis in randomised controlled trials: importance, indications, and interpretation. Lancet 365 (2005) 176-186
43. Ahmed A., Kiefe C.I., Allman R.M., et al. Survival benefits of angiotensin-converting enzyme inhibitors in older heart failure patients with perceived contraindications. J Am Geriatr Soc 50 (2002) 1659-1666
44. McAlister F.A., Ezekowitz J., Tonelli M., et al. Renal insufficiency and heart failure: prognostic and therapeutic implications from a prospective cohort study. Circulation 109 (2004) 1004-1009
45. Ahmed A., Love T.E., Sui X., et al. Effects of angiotensin-converting enzyme inhibitors in systolic heart failure patients with chronic kidney disease: a propensity score analysis. J Card Fail 12 (2006) 499-506
46. Berger A.K., Duval S., Manske C., et al. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients with congestive heart failure and chronic kidney disease. Am Heart J 153 (2007) 1064-1073
47. Solomon S.D., Rice M.M., Jablonski K.A., et al. Renal function and effectiveness of angiotensin-converting enzyme inhibitor therapy in patients with chronic stable coronary disease in the Prevention of Events with ACE inhibition (PEACE) trial. Circulation 114 (2006) 26-31
48. Coresh J., Selvin E., Stevens L.A., et al. Prevalence of chronic kidney disease in the United States. JAMA 298 (2007) 2038-2047
49. Centers for Disease Control and Prevention. Prevalence of chronic kidney disease and associated risk factors-United States, 1999-2004. MMWR Morb Mortal Wkly Rep 56 (2007) 161-165
50. McClellan W., Warnock D.G., McClure L., et al. Racial differences in the prevalence of chronic kidney disease among participants in the Reasons for Geographic and Racial Differences in Stroke (REGARDS) Cohort Study. J Am Soc Nephrol 17 (2006) 1710-1715
51. Shlipak M.G., Fried L.F., Cushman M., et al. Cardiovascular mortality risk in chronic kidney disease: comparison of traditional and novel risk factors. JAMA 293 (2005) 1737-1745
52. Stevens P.E., O'Donoghue D.J., de Lusignan S., et al. Chronic kidney disease management in the United Kingdom: NEOERICA project results. Kidney Int 72 (2007) 92-99
53. Carter J.L., O'Riordan S.E., Eaglestone G.L., et al. Chronic kidney disease prevalence in a UK Residential Care Home Population. Nephrol Dial Transplant 23 (2007) 1257-1264
54. Chadban S.J., Briganti E.M., Kerr P.G., et al. Prevalence of kidney damage in Australian adults: the AusDiab kidney study. J Am Soc Nephrol 14 (2003) S131-S138
55. Imai E., Horio M., Iseki K., et al. Prevalence of chronic kidney disease (CKD) in the Japanese general population predicted by the MDRD equation modified by a Japanese coefficient. Clin Exp Nephrol 11 (2007) 156-163
56. Zhang L., Zuo L., Xu G., et al. Community-based screening for chronic kidney disease among populations older than 40 years in Beijing. Nephrol Dial Transplant 22 (2007) 1093-1099
57. Rao M., and Pereira B.J. Chronic kidney disease in India-a hidden epidemic. Indian J Med Res 126 (2007) 6-9
58. Krumholz H.M., Chen J., Chen Y.T., et al. Predicting one-year mortality among elderly survivors of hospitalization for an acute myocardial infarction: results from the Cooperative Cardiovascular Project. J Am Coll Cardiol 38 (2001) 453-459
59. Glynn L.G., Reddan D., Newell J., et al. Chronic kidney disease and mortality and morbidity among patients with established cardiovascular disease: a West of Ireland community-based cohort study. Nephrol Dial Transplant 22 (2007) 2586-2594
60. Reddan D.N., Szczech L.A., Tuttle R.H., et al. Chronic kidney disease, mortality, and treatment strategies among patients with clinically significant coronary artery disease. J Am Soc Nephrol 14 (2003) 2373-2380
61. Liu H., Yu J., Chen F., et al. Inpatients with coronary heart disease have a high prevalence of chronic kidney disease based on estimated glomerular filtration rate (eGFR) in China. Heart Vessels 22 (2007) 223-228
62. Coca S.G., Krumholz H.M., Garg A.X., et al. Underrepresentation of renal disease in randomized controlled trials of cardiovascular disease. JAMA 296 (2006) 1377-1384
63. Charytan D., and Kuntz R.E. The exclusion of patients with chronic kidney disease from clinical trials in coronary artery disease. Kidney Int 70 (2006) 2021-2030
64. Masoudi F.A., Havranek E.P., Wolfe P., et al. Most hospitalized older persons do not meet the enrollment criteria for clinical trials in heart failure. Am Heart J 146 (2003) 250-257
65. Fonarow G.C., Abraham W.T., Albert N.M., et al. Influence of a performance-improvement initiative on quality of care for patients hospitalized with heart failure: results of the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients With Heart Failure (OPTIMIZE-HF). Arch Intern Med 167 (2007) 1493-1502
66. Masoudi F.A., Baillie C.A., Wang Y., et al. The complexity and cost of drug regimens of older patients hospitalized with heart failure in the United States, 1998-2001. Arch Intern Med 165 (2005) 2069-2076
67. Rathore S.S., Foody J.M., Wang Y., et al. Race, quality of care, and outcomes of elderly patients hospitalized with heart failure. JAMA 289 (2003) 2517-2524
68. Ahmed A., DeShazo W.R., Dell'Italia L.J., et al. Discharge prescription of beta blockers reduces mortality in hospitalized older adults with systolic heart failure: a propensity score analysis. Circulation 112 (2005) II-353
69. Pfeffer M.A., Swedberg K., Granger C.B., et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 362 (2003) 759-766
70. Khan N.A., Ma I., Thompson C.R., et al. Kidney function and mortality among patients with left ventricular systolic dysfunction. J Am Soc Nephrol 17 (2006) 244-253
71. The Beta-Blocker Evaluation of Survival Trial Investigators. A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. N Engl J Med 344 (2001) 1659-1667
72. Pitt B., Remme W., Zannad F., et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 348 (2003) 1309-1321
73. Gottdiener J.S., McClelland R.L., Marshall R., et al. Outcome of congestive heart failure in elderly persons: influence of left ventricular systolic function. The Cardiovascular Health Study. Ann Intern Med 137 (2002) 631-639
74. McKee P.A., Castelli W.P., McNamara P.M., et al. The natural history of congestive heart failure: the Framingham study. N Engl J Med 285 (1971) 1441-1446
75. Ahmed A, Howard VJ, Zhang R, et al. Prevalence of heart failure in REGARDS: a unique opportunity to study racial and geographical variations in heart failure epidemiology. Presented at the 48th Cardiovascular Disease Epidemiology and Prevention Annual Conference. Colorado Springs, Colorado, March 11-15, 2008.
76. Bibbins-Domingo K., Lin F., Vittinghoff E., et al. Renal insufficiency as an independent predictor of mortality among women with heart failure. J Am Coll Cardiol 44 (2004) 1593-1600
77. Jose P., Skali H., Anavekar N., et al. Increase in creatinine and cardiovascular risk in patients with systolic dysfunction after myocardial infarction. J Am Soc Nephrol 17 (2006) 2886-2891
78. Fox C.S., Larson M.G., Leip E.P., et al. Predictors of new-onset kidney disease in a community-based population. JAMA 291 (2004) 844-850
79. Herzog C.A., Ma J.Z., and Collins A.J. Comparative survival of dialysis patients in the United States after coronary angioplasty, coronary artery stenting, and coronary artery bypass surgery and impact of diabetes. Circulation 106 (2002) 2207-2211
80. Goodman W.G., Goldin J., Kuizon B.D., et al. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 342 (2000) 1478-1483
81. Bongartz L.G., Cramer M.J., Doevendans P.A., et al. The severe cardiorenal syndrome: Guyton revisited. Eur Heart J 26 (2005) 11-17
82. Heywood J.T. The cardiorenal syndrome: lessons from the ADHERE database and treatment options. Heart Fail Rev 9 (2004) 195-201
83. Schrier R.W. Cardiorenal versus renocardiac syndrome: is there a difference?. Nat Clin Pract Nephrol 3 (2007) 637
84. Shlipak M.G., and Massie B.M. The clinical challenge of cardiorenal syndrome. Circulation 110 (2004) 1514-1517
85. Fried L.F., Shlipak M.G., Crump C., et al. Renal insufficiency as a predictor of cardiovascular outcomes and mortality in elderly individuals. J Am Coll Cardiol 41 (2003) 1364-1372